Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010.

The GAAP net loss for the quarter ended March 31, 2011 was $111.8 million, or $0.77 per share, compared to $125.7 million, or $0.96 per share for the quarter ended March 31, 2010 (which included a non-cash charge of $68 million loss from valuation of warrant liability). On a pro-forma basis, excluding non-cash expenses associated with depreciation and amortization, non-cash imputed interest expense, and non-cash deferred stock compensation, Dendreon’s net loss was approximately $85 million or $0.59 per share. Dendreon's total operating expenses for the quarter ended March 31, 2011 were $112.9 million compared to $57.6 million for the three months ended March 31, 2010.

As of March 31, 2011, Dendreon had approximately $779.0 million in cash, cash equivalents, and short-term and long-term investments compared to $277.3 million as of December 31, 2010.

Recent Highlights:

  • In addition to the $28.1 million in revenue in the first quarter, sales of PROVENGE® (sipuleucel-T) in April 2011 were approximately $15 million, reflecting increasing demand and increasing utilization of its newly approved capacity.  Dendreon continues to expect revenue this year of between $350-400 million with approximately half of that anticipated in the fourth quarter.
  • The number of accounts infusing PROVENGE as of March 31, 2011 increased from approximately 50 to approximately 135 and we are on track to meet our goal of 225 sites infusing PROVENGE by the end of Q2.
  • The U.S. Food and Drug Administration (FDA) approved the expanded New Jersey manufacturing facility.  The 36 a
    '/>"/>

  • SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
    2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
    3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
    4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
    5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
    6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
    7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
    8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
    9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
    10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
    11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Two champions of science, technology, engineering, and mathematics ... competition for middle and high school students designed to ... The competition presents students with real-world problems experienced by ... and Sciences is a program administered by the ...
    (Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
    (Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
    (Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
    Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... a leader in health,care quality management solutions for ... approved the company as a vendor for the ... will automate the collection and submission of clinical,information ... to,hand-write data collection worksheets or manually enter data ...
    ... relapse, with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic ... filings, - Historically, one ... ... therapeutic approaches to patients with rare diseases, EAST ...
    ... 27, Peakdale Molecular Ltd (CHAPEL-EN-LE-FRITH, UK) a ... pharmaceutical and,biotechnology industry, and ChemPrintCo LLC (MILPITAS, ... products and systems for the biotechnology,industry, today ... is an online based storefront which allows ...
    Cached Biology Technology:MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative 2Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 2Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 3Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 5Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 6Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 7Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 8Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 9Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 10Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 11Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 12Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 3
    (Date:4/17/2014)... A new modeling study suggests that fish consumption ... infant exposure to long-lived contaminants like persistent organic ... a team of researchers including University of Toronto ... Wania, looks at how different levels of environmental ... behavior of chemicals in the body influenced exposure ...
    (Date:4/17/2014)... State University engineer has developed a patented technique ... explosive devices. The same technique could help police ... M. and Kay L. Theede chair in engineering ... and his research team have created a template-based ... car trunks. The distance detection method called ...
    (Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
    Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
    ... hold its 93rd annual meeting on Aug. 3-8, 2008, ... 1915 to promote the practice and awareness of ecological ... nature of ecology and linking research with education. A ... presented at the meeting, including a number of presentations ...
    ... research group led by Stephen Dalton, professor and Georgia ... University of Georgia, has been awarded $9.2 million as ... National Institute of General Medical Sciences, part of the ... the department of biochemistry and molecular biology, will address ...
    ... As Ohio and Michigan fruit and vegetable farms ... about the eating choices of Latino migrant children for ... this summer will help migrant families understand why their ... and contribute to new interventions to combat this serious ...
    Cached Biology News:ESA to feature wide range of UW-Madison presentations 2ESA to feature wide range of UW-Madison presentations 3ESA to feature wide range of UW-Madison presentations 4ESA to feature wide range of UW-Madison presentations 5ESA to feature wide range of UW-Madison presentations 6ESA to feature wide range of UW-Madison presentations 7ESA to feature wide range of UW-Madison presentations 8UGA researchers win $9.2 million stem cell grant from NIH 2Case Western Reserve University study looks at keeping migrant workers' children healthy 2
    The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
    Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
    ... save space and organize gloves, safety ... They are the perfect benchtop storage ... labs, processing and manufacturing. Clear static-dissipative ... particles they attract. Many other sizes ...
    ...
    Biology Products: